⏱ News is delayed by 15 minutes. Sign in for real-time access.
Sign in
SCYX News
SCYNEXIS, Inc.
SCYNEXIS to Participate in the 3rd Annual Guggenheim Healthcare Innovation Conference
globenewswire.com
SCYX
SCYNEXIS Completes Phase 1 Study of Intravenous SCY-247, a Novel, Triterpenoid Antifungal in Development for Treatment and Prevention of Invasive Fungal Diseases
globenewswire.com
SCYX
SCYNEXIS to Feature SCY-247 in a Pipeline Presentation at IDWeek
globenewswire.com
SCYX
Poxel Reports Revenue for the Third Quarter of 2026
businesswire.com
SCYX
SCYNEXIS Announces Phase 1 Study Results for SCY-770, a Novel, Highly Selective, Oral Direct AMPK Activator for the Treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD)
globenewswire.com
SCYX
Form 8-K
sec.gov
SCYX
SCYNEXIS Awarded BARDA Contract Providing Up to $214 Million in Non-Dilutive Funding for the Development of SCY-247
globenewswire.com
SCYX
Form 8-K
sec.gov
SCYX
SCYNEXIS Appoints Seasoned Industry Veteran Steven K. Burke, M.D., to its Board of Directors
globenewswire.com
SCYX
SCYNEXIS Appoints Todd Minga, M.D., as Senior Vice President, Research & Development
globenewswire.com
SCYX